The clinical performance is complex and often involves multiple systems. Early identification and standardization are essential for improving prognosis. The diagnosis of this disease requires a combination of clinical performance, imaging, laboratory testing and pathological evaluation.
The platform can assist in bringing together a team of authoritative experts at home and abroad to provide accurate diagnosis and treatment. In recent years, with the development of therapeutic, immune-regulatory therapy and precision medicine, many previously difficult-to-treat blood tumour diseases have been significantly improved. Treatment requires close monitoring of efficacy and adverse reactions and timely adjustment according to changes in the disease.
Multidisciplinary collaboration (MDT) is particularly important for the integrated management of HLISRT. The platform serves a team of domestic and foreign experts in the field of blood tumours in China, providing the following services to patients: 2. Visiting China: arranging face-to-face treatment with authoritative experts, developing individualized treatment plans; 3.
Full-service: providing one-stop services such as medical translation, medical care, accommodation arrangements; 4. Long-term follow-up: establishing a chronic disease management archive, continuous monitoring of disease changes and treatment effects.